KIT and chronic myelogenous leukemia, BCR-ABL1 positive: In 2017, end-point clinical trial indicates that nilotinib could be an additional treatment option for KIT-mutated advanced patients or for intolerant patients to imatinib and in contrast to what have been observed in CML patients, nilotinib did not show any better response compared to imatinib and further proposed to investigate the potential role of combining c-KIT inhibitor to immunotherapy as a next step (Table 3) [71].